Screener
Tarsus Pharmaceuticals, Inc. TARS Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed March 17, 2023.
- Filed
- Mar 17, 2023
- Fiscal year
- FY2023
- Accession
- 0001819790-23-000007
| Line item | Year ended December 31, 2022 | Year ended December 31, 2021 |
|---|---|---|
| Accretion of term loan-related costs | 309 | — |
| Non-cash lease expense | 464 | 294 |
| Loss on lease termination | — | 2 |
| Loss on disposal of property and equipment | — | 70 |
| Amortization of discount on available-for-sale debt securities | (1,316) | — |
| Unrealized loss on equity investment | 268 | 591 |
| Change in fair value of equity warrants issued by licensee | 501 | 987 |
| Unrealized gain from transactions denominated in a foreign currency | 1 | (2) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s gain/loss on asset sales?
- Tarsus Pharmaceuticals, Inc. (TARS) reported gain/loss on asset sales of $0 in Q4 2022.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude